rewirebio.iobenchmarks
Contested result

PolyPhen-2 and SIFT: Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) reverses the order

  • Low severity
  • Not yet reviewed
  • Ordering reversal
  • Different tasks across studies

Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML) ranks SIFT above PolyPhen-2 in 5 of 6 comparisons; other studies rank PolyPhen-2 above SIFT in 24 of 30.

An automatic lead, not a finding of error. The results below are shown as published, everywhere on the site, until a reviewer decides otherwise.

Which studies agree

3 papers rank PolyPhen-2 above SIFT in 24 of their 31 comparisons and SIFT higher in 6; 1 is a tie. Livesey and Marsh 2025 ranks SIFT above PolyPhen-2 in 5 of its 6 comparisons and PolyPhen-2 higher in 1.

Papers grouped by which system they rank higher: PolyPhen-2 or SIFTRank PolyPhen-2 higher: Comprehensive assessment…, An openly licensed benchmark…, Clinical likelihood ratios and balanced…. Rank SIFT higher: Livesey and Marsh 2025 (disagrees). Mixed: none.Rank PolyPhen-2 higherMixedRank SIFT higherComprehensive assessment…Comprehensive assessment of computational algorithms in predicting cancer driver mutationsAn openly licensedbenchmark…An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer driversClinical likelihoodratios and balanced…Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genesLivesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)
  • Rank PolyPhen-2 higher (3): Comprehensive assessment…, An openly licensed benchmark…, Clinical likelihood ratios and balanced…
  • Rank SIFT higher (1): Livesey and Marsh 2025 (disagrees)
  • Mixed (0): none

Each paper sits where at least two thirds of its comparisons point; Mixed means neither model reaches two thirds. The larger, outlined dot is the paper that disagrees.

Comparisons in which each paper scores PolyPhen-2 or SIFT higherLivesey and Marsh 2025 (disagrees): PolyPhen-2 higher in 1, SIFT higher in 5, 0 ties. Comprehensive assessment…: PolyPhen-2 higher in 15, SIFT higher in 5, 0 ties. An openly licensed benchmark…: PolyPhen-2 higher in 5, SIFT higher in 0, 1 tie. Clinical likelihood ratios and balanced…: PolyPhen-2 higher in 4, SIFT higher in 1, 0 ties.Disagrees: Livesey and Marsh 2025Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)1 PolyPhen-2 higher15 SIFT higher5Comprehensive assessment…Comprehensive assessment of computational algorithms in predicting cancer driver mutations15 PolyPhen-2 higher155 SIFT higher5An openly licensed benchmark…An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers5 PolyPhen-2 higher51 tie1Clinical likelihood ratios and balanced…Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes4 PolyPhen-2 higher41 SIFT higher1
PolyPhen-2 higherTieSIFT higherNumbers are counts of comparisons; the outlined bar is the paper that disagrees.
Comparisons in Livesey and Marsh 2025 (6)
ProtocolDatasetMetricPolyPhen-2SIFTHigher
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets), percent48.352.2SIFT
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets), percent8.476.85PolyPhen-2
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only), percent46.249.9SIFT
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only), percent5053.6SIFT
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions onlyLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only), percent48.452.2SIFT
Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filledLivesey and Marsh 2025 human DMS benchmark set (36 proteins)Pairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score), percent49.753.6SIFT
Comparisons in Comprehensive assessment… (20)
ProtocolDatasetMetricPolyPhen-2SIFTHigher
OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Accuracy (OncoKB benchmark (positive set not stated), default categorical calls), fraction0.640.61PolyPhen-2
OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Negative predictive value (OncoKB benchmark (positive set not stated), default categorical calls), fraction0.790.75PolyPhen-2
OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Precision (OncoKB benchmark (positive set not stated), default categorical calls), fraction0.60.58PolyPhen-2
OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Recall (OncoKB benchmark (positive set not stated), default categorical calls), fraction0.930.89PolyPhen-2
OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Specificity (OncoKB benchmark (positive set not stated), default categorical calls), fraction0.390.41SIFT
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Accuracy (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.630.61PolyPhen-2
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.630.61PolyPhen-2
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Precision (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.620.61PolyPhen-2
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Recall (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.640.63PolyPhen-2
OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)OncoKB-annotated somatic missense mutations (oncogenic, likely oncogenic and likely neutral)Specificity (OncoKB benchmark (positive set not stated), median-score threshold), fraction0.620.6PolyPhen-2
Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Accuracy (cell viability drivers versus neutral, default categorical calls), fraction0.590.58PolyPhen-2
Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Negative predictive value (cell viability drivers versus neutral, default categorical calls), fraction0.70.66PolyPhen-2
Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Precision (cell viability drivers versus neutral, default categorical calls), fraction0.570.54PolyPhen-2
Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Recall (cell viability drivers versus neutral, default categorical calls), fraction0.880.8PolyPhen-2
Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Specificity (cell viability drivers versus neutral, default categorical calls), fraction0.380.48SIFT
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Accuracy (cell viability drivers versus neutral, median-score threshold), fraction0.590.6SIFT
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Negative predictive value (cell viability drivers versus neutral, median-score threshold), fraction0.590.61SIFT
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Precision (cell viability drivers versus neutral, median-score threshold), fraction0.590.58PolyPhen-2
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Recall (cell viability drivers versus neutral, median-score threshold), fraction0.590.67SIFT
Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Missense mutations with Ba/F3 and MCF10A cell viability calls (published and new)Specificity (cell viability drivers versus neutral, median-score threshold), fraction0.590.53PolyPhen-2
Comparisons in An openly licensed benchmark… (6)
ProtocolDatasetMetricPolyPhen-2SIFTHigher
CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, all genes), unitless0.8260.808PolyPhen-2
CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, all genes), unitless0.550.541PolyPhen-2
CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, oncogenes (gain of function)), unitless0.820.786PolyPhen-2
CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, oncogenes (gain of function)), unitless0.6020.572PolyPhen-2
CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAUROC (CGC missense, tumour suppressors (loss of function)), unitless0.8520.847Tie
CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Missense variants in 768 Cancer Gene Census genes with open oncogenicity labelsAverage precision (CGC missense, tumour suppressors (loss of function)), unitless0.4820.471PolyPhen-2
Comparisons in Clinical likelihood ratios and balanced… (5)
ProtocolDatasetMetricPolyPhen-2SIFTHigher
BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)BRCA1 functional truth set: 1641 missense variants classed deleterious or tolerated by HAP1 cell survival after saturation genome editingBenignity likelihood ratio (Source 'negative likelihood ratio' (TNR/FNR): likelihood ratio for benignity of a tolerated call, BRCA1 functional truth set), unitless27.623.9PolyPhen-2
BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)BRCA1 functional truth set: 1641 missense variants classed deleterious or tolerated by HAP1 cell survival after saturation genome editingFalse negatives (Functionally deleterious BRCA1 variants called tolerated), count23PolyPhen-2
BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)BRCA1 functional truth set: 1641 missense variants classed deleterious or tolerated by HAP1 cell survival after saturation genome editingLikelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA1 functional truth set), unitless1.281.23PolyPhen-2
BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)BRCA2 functional truth set: 188 missense variants classed deleterious or tolerated by Homology-directed repairFalse negatives (Functionally deleterious BRCA2 variants called tolerated), count10SIFT
BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)BRCA2 functional truth set: 188 missense variants classed deleterious or tolerated by Homology-directed repairLikelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA2 functional truth set), unitless1.281.24PolyPhen-2

What disagrees

Other studies
rank PolyPhen-2 above SIFT in 24 of 30 comparisons
This study
ranks SIFT above PolyPhen-2 in 5 of 6 comparisons
Compared
PolyPhen-2, SIFT
Study that disagrees
Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML), Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8)
Other studies
9 studiesClinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes, Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx), Comprehensive assessment of computational algorithms in predicting cancer driver mutations, Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB), Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability), Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability), Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB), An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers, OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)
Rule
Ordering reversal; different tasks across studies
Model identity
Matched across studies partly through links not yet reviewed

The compared numbers

Each value links to its result record and source. Compare values within one protocol; the rule compares rankings, not raw values across protocols.

In the study that disagrees (12)
StudyToolProtocol or benchmarkMetricValue
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)48.3
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsPairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)8.47
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, 36 human DMS sets)52.2
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, all 36 DMS setsPairwise win rate (average pairwise win rate against the five top-ranked VEPs (column top_5_winrate; the five are not listed in the table), |Spearman| with DMS on shared variants, 36 human DMS sets)6.85
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)46.2
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, direct assays onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, direct DMS assays only)49.9
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)50
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, indirect assays onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, indirect DMS assays only)53.6
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filledPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)49.7
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions with gaps filledPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS, SNV-accessible substitutions, missing predictions filled with the VEP's most benign score)53.6
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)PolyPhen2_HumVar (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)48.4
Livesey and Marsh 2025, Supplementary Material 2 (Tables S1-S8); Livesey and Marsh 2025, Genome Biology 26:104 (Europe PMC full text XML)SIFT4G (Livesey and Marsh 2025)Livesey and Marsh 2025 DMS benchmark: pairwise |Spearman| win rate, SNV-accessible substitutions onlyPairwise win rate (average pairwise win rate against all other VEPs, |Spearman| with DMS on shared variants, SNV-accessible substitutions only)52.2
In the other studies (66 results)
In the other studies
StudyToolProtocol or benchmarkMetricValue
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HDIV (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)Benignity likelihood ratio (Source 'negative likelihood ratio' (TNR/FNR): likelihood ratio for benignity of a tolerated call, BRCA1 functional truth set)27.6
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HDIV (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)False negatives (Functionally deleterious BRCA1 variants called tolerated)2
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HDIV (Cubuk et al. 2021)BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)False negatives (Functionally deleterious BRCA2 variants called tolerated)1
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HVAR (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)Likelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA1 functional truth set)1.28
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HVAR (Cubuk et al. 2021)BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)False negatives (Functionally deleterious BRCA2 variants called tolerated)1
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)Polyphen2_HVAR (Cubuk et al. 2021)BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)Likelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA2 functional truth set)1.28
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)SIFT (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)Benignity likelihood ratio (Source 'negative likelihood ratio' (TNR/FNR): likelihood ratio for benignity of a tolerated call, BRCA1 functional truth set)23.9
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)SIFT (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)False negatives (Functionally deleterious BRCA1 variants called tolerated)3
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)SIFT (Cubuk et al. 2021)BRCA1 functional truth set, binary in silico calls (Cubuk et al. 2021)Likelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA1 functional truth set)1.23
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)SIFT (Cubuk et al. 2021)BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)False negatives (Functionally deleterious BRCA2 variants called tolerated)0
Clinical likelihood ratios and balanced accuracy for 44 in silico tools against multiple large-scale functional assays of cancer susceptibility genes; Cubuk et al. 2021, Supplementary tables 1-13 (41436_2021_1265_MOESM3_ESM.xlsx)SIFT (Cubuk et al. 2021)BRCA2 functional truth set, binary in silico calls (Cubuk et al. 2021)Likelihood ratio (Positive likelihood ratio of a deleterious call (TPR/FPR), BRCA2 functional truth set)1.24
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Negative predictive value (OncoKB benchmark (positive set not stated), default categorical calls)0.79
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Recall (OncoKB benchmark (positive set not stated), default categorical calls)0.93
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Accuracy (OncoKB benchmark (positive set not stated), median-score threshold)0.63
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold)0.63
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Precision (OncoKB benchmark (positive set not stated), median-score threshold)0.62
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Recall (OncoKB benchmark (positive set not stated), median-score threshold)0.64
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HDIV (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Specificity (OncoKB benchmark (positive set not stated), median-score threshold)0.62
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HDIV (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Accuracy (cell viability drivers versus neutral, default categorical calls)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HDIV (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Negative predictive value (cell viability drivers versus neutral, default categorical calls)0.7
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HDIV (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Recall (cell viability drivers versus neutral, default categorical calls)0.88
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)Polyphen2_HVAR (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Accuracy (OncoKB benchmark (positive set not stated), default categorical calls)0.64
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)Polyphen2_HVAR (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Precision (OncoKB benchmark (positive set not stated), default categorical calls)0.6
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)Polyphen2_HVAR (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Specificity (OncoKB benchmark (positive set not stated), default categorical calls)0.39
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)Polyphen2_HVAR (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Precision (OncoKB benchmark (positive set not stated), median-score threshold)0.62
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Accuracy (cell viability drivers versus neutral, default categorical calls)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Precision (cell viability drivers versus neutral, default categorical calls)0.57
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Specificity (cell viability drivers versus neutral, default categorical calls)0.38
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Accuracy (cell viability drivers versus neutral, median-score threshold)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Negative predictive value (cell viability drivers versus neutral, median-score threshold)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Precision (cell viability drivers versus neutral, median-score threshold)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Recall (cell viability drivers versus neutral, median-score threshold)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)Polyphen2_HVAR (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Specificity (cell viability drivers versus neutral, median-score threshold)0.59
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Accuracy (OncoKB benchmark (positive set not stated), default categorical calls)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Negative predictive value (OncoKB benchmark (positive set not stated), default categorical calls)0.75
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Recall (OncoKB benchmark (positive set not stated), default categorical calls)0.89
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Accuracy (OncoKB benchmark (positive set not stated), median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Recall (OncoKB benchmark (positive set not stated), median-score threshold)0.63
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)SIFT (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Negative predictive value (cell viability drivers versus neutral, default categorical calls)0.66
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)SIFT (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Recall (cell viability drivers versus neutral, default categorical calls)0.8
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)SIFT (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Specificity (cell viability drivers versus neutral, median-score threshold)0.53
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Accuracy (OncoKB benchmark (positive set not stated), default categorical calls)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Precision (OncoKB benchmark (positive set not stated), default categorical calls)0.58
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 10: Performance metrics of 17 algorithms, default categories, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), default categorical calls (Chen et al. 2020 Additional file 10)Specificity (OncoKB benchmark (positive set not stated), default categorical calls)0.41
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Accuracy (OncoKB benchmark (positive set not stated), median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Negative predictive value (OncoKB benchmark (positive set not stated), median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Precision (OncoKB benchmark (positive set not stated), median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 9: Performance metrics of 33 algorithms, median-score threshold, benchmark 2 (OncoKB)SIFT4G (Chen et al. 2020)OncoKB benchmark (positive set not stated), median-score threshold (Chen et al. 2020 Additional file 9)Specificity (OncoKB benchmark (positive set not stated), median-score threshold)0.6
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Accuracy (cell viability drivers versus neutral, default categorical calls)0.58
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Precision (cell viability drivers versus neutral, default categorical calls)0.54
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 22: Performance metrics of 17 algorithms, default categories, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, default categorical calls (Chen et al. 2020 Additional file 22)Specificity (cell viability drivers versus neutral, default categorical calls)0.48
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Accuracy (cell viability drivers versus neutral, median-score threshold)0.6
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Negative predictive value (cell viability drivers versus neutral, median-score threshold)0.61
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Precision (cell viability drivers versus neutral, median-score threshold)0.58
Comprehensive assessment of computational algorithms in predicting cancer driver mutations; Chen et al. 2020, Additional file 21: Performance metrics of 33 algorithms, median-score threshold, benchmark 5 (cell viability)SIFT4G (Chen et al. 2020)Cell viability drivers versus neutral, median-score threshold (Chen et al. 2020 Additional file 21)Recall (cell viability drivers versus neutral, median-score threshold)0.67
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)Polyphen2_HVAR rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, all genes)0.55
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)Polyphen2_HVAR rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)AUROC (CGC missense, all genes)0.826
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)Polyphen2_HVAR rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, oncogenes (gain of function))0.602
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)Polyphen2_HVAR rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)AUROC (CGC missense, oncogenes (gain of function))0.82
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)Polyphen2_HVAR rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, tumour suppressors (loss of function))0.482
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)SIFT4G rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, all genes)0.541
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)SIFT4G rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, all genes (Lee 2026, OncoCal tool_performance.tsv)AUROC (CGC missense, all genes)0.808
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)SIFT4G rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, oncogenes (gain of function))0.572
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)SIFT4G rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, oncogenes (gain of function) (Lee 2026, OncoCal tool_performance.tsv)AUROC (CGC missense, oncogenes (gain of function))0.786
An openly licensed benchmark and per-gene calibration map for missense pathogenicity predictors on activating cancer drivers; OncoCal repository, tables/tool_performance.tsv (per-tool AUROC and AUPRC by gene role)SIFT4G rank score, dbNSFP 5.3.1a (Lee 2026)CGC missense oncogenicity, tumour suppressors (loss of function) (Lee 2026, OncoCal tool_performance.tsv)Average precision (CGC missense, tumour suppressors (loss of function))0.471

Follow-up

Current state: Not yet reviewed.

No one has reviewed this finding yet.

How to help resolve this

If you know why these studies disagree, for example a different population, metric or preprocessing step, or you have a corrected value, tell us through the contribution form. A reviewer checks every submission against its source before anything changes, and the step is added to the follow-up above.

Finding discrepancy-b71700d5c548f5ef · All contested results · How findings are made and followed up